Januvia

+ 1 more variants

• Gastrointestinal Upset: Nausea, diarrhea, abdominal pain, or flatulence (gas). These symptoms are more common when sitagliptin is taken in combination with metformin.
• Hypoglycemia: While sitagliptin alone rarely causes low blood sugar, the risk increases significantly when it is used with a sulfonylurea or insulin. Symptoms include shakiness, sweating, fast heartbeat, and confusion.
• Peripheral Edema: Swelling of the hands, ankles, or feet, particularly when used in combination with thiazolidinediones (like pioglitazone).

• Hypersensitivity Reactions: Rare but serious allergic reactions including anaphylaxis, angioedema (swelling of the face, lips, or tongue), and exfoliative skin conditions.
• Elevated Liver Enzymes: Occasional reports of increases in hepatic enzymes, though clinical liver injury is extremely rare.
• Acute Renal Failure: There have been post-marketing reports of worsening renal function, sometimes requiring dialysis.

> Warning: Stop taking Sitagliptin and call your doctor immediately if you experience any of these serious conditions:

• Pancreatitis (Inflammation of the Pancreas): This is a severe and potentially life-threatening condition. Symptoms include persistent, severe abdominal pain that may radiate to your back, with or without vomiting. If pancreatitis is suspected, sitagliptin should be discontinued immediately and not restarted.
• Heart Failure: Some DPP-4 inhibitors have been linked to an increased risk of heart failure. Symptoms include shortness of breath (especially when lying down), unusual tiredness, or rapid weight gain with swelling in the legs or abdomen.
• Severe Joint Pain (Arthralgia): Some patients develop disabling joint pain. This can occur days or even years after starting the drug. The pain typically resolves after stopping the medication.
• Bullous Pemphigoid: This is a skin reaction that causes large, fluid-filled blisters. It requires immediate dermatological evaluation and discontinuation of the drug.
• Severe Allergic Reactions: Rash, hives, or swelling of the face, lips, tongue, and throat that may cause difficulty breathing or swallowing.

Long-term use of sitagliptin is generally considered safe based on cardiovascular outcome trials like the TECOS study (2015), which followed over 14,000 patients for an average of 3 years. The study found no increased risk of major adverse cardiovascular events. However, long-term monitoring for renal function and skin integrity is recommended, as rare conditions like bullous pemphigoid may take time to manifest.

As of the latest FDA updates in 2024, there are no FDA black box warnings for sitagliptin. However, the warnings regarding pancreatitis and heart failure are considered high-priority precautions that healthcare providers must discuss with patients before initiating therapy.

Report any unusual symptoms or changes in your health to your healthcare provider immediately. Regular follow-up appointments are essential to monitor for both the efficacy of the drug and the presence of any underlying side effects.

An association between DPP-4 inhibitor treatment and heart failure has been observed in cardiovascular outcomes trials for other members of the drug class. While the TECOS trial for sitagliptin did not show a statistically significant increase in heart failure hospitalizations, patients with a history of heart or kidney disease should be monitored closely for signs such as edema and dyspnea (shortness of breath).

Renal Effects

Sitagliptin is renally excreted. To avoid excessive accumulation of the drug, dosage adjustments are required in patients with moderate to severe renal insufficiency. There have been reports of acute renal failure in patients taking sitagliptin, sometimes in those who were already at risk for kidney problems.

Severe Allergic Reactions

Serious hypersensitivity reactions have occurred. These reactions include anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. These reactions typically occur within the first 3 months after initiation of treatment, but can occur after the first dose.

To ensure the safe use of sitagliptin, healthcare providers will typically order the following tests:

• HbA1c: Tested every 3 to 6 months to evaluate long-term blood sugar control.
• Renal Function Tests: Serum creatinine and eGFR should be assessed before starting the drug and at least annually thereafter. More frequent monitoring is required for those with existing kidney disease.
• Blood Glucose: Routine self-monitoring of blood glucose (finger sticks) as directed by your doctor.

Sitagliptin itself is unlikely to affect your ability to drive or use machines. However, if you are taking it with other diabetes medications (like insulin or sulfonylureas), your blood sugar could drop too low (hypoglycemia). Hypoglycemia can cause dizziness, blurred vision, and impaired concentration. Do not drive or operate heavy machinery until you know how sitagliptin affects your blood sugar levels.

Alcohol can interfere with blood sugar control and increase the risk of both hypoglycemia and pancreatitis. Excessive alcohol consumption should be avoided while taking sitagliptin. Discuss your alcohol intake habits with your healthcare provider to determine what is safe for you.

Do not stop taking sitagliptin suddenly without consulting your doctor. Stopping the medication can cause your blood sugar levels to rise rapidly (hyperglycemia), which increases the risk of long-term diabetes complications like nerve damage, kidney failure, and vision loss. There is no known withdrawal syndrome, but blood sugar must be managed through alternative means if sitagliptin is discontinued.

> Important: Discuss all your medical conditions, especially any history of kidney disease, heart failure, or pancreas problems, with your healthcare provider before starting Sitagliptin.

Digoxin

• Mechanism: Sitagliptin may cause a slight increase in the area under the curve (AUC) and peak concentration (Cmax) of digoxin.
• Clinical Consequence: Potential for digoxin toxicity, which can cause heart rhythm issues.
• Management: Patients receiving digoxin should be monitored for toxicity, although no routine dose adjustment of digoxin is usually recommended.

Carbonic Anhydrase Inhibitors (e.g., Topiramate, Zonisamide)

• Mechanism: These drugs can increase the risk of metabolic acidosis.
• Clinical Consequence: May theoretically interfere with glucose metabolism or increase renal stress.
• Management: Monitor blood sugar and renal function more closely.

Sitagliptin does not have significant interactions with specific foods. It can be taken with or without food. Unlike some other medications, it does not interact with grapefruit juice or dairy products. However, maintaining a consistent carbohydrate-controlled diet is essential for the medication to work effectively.

• St. John's Wort: May slightly decrease the levels of sitagliptin by inducing CYP3A4, though the clinical effect is likely minimal since sitagliptin is mostly excreted unchanged.
• Fenugreek and Ginseng: These supplements have natural glucose-lowering properties. Taking them with sitagliptin may increase the risk of hypoglycemia.
• Glucosamine: Some studies suggest glucosamine may interfere with blood sugar control. Monitor glucose levels if starting this supplement.

Sitagliptin is not known to interfere with common laboratory tests. However, it will lower your HbA1c and blood glucose readings, which is the intended therapeutic effect. Always inform laboratory personnel and your doctors of all medications you are taking.

For each major interaction, the primary concern is either the management of blood glucose levels (preventing hypoglycemia) or the preservation of renal function. Because sitagliptin is primarily cleared by the kidneys, any drug that significantly impairs kidney function (such as high-dose NSAIDs like ibuprofen or certain antibiotics) can indirectly increase sitagliptin levels in the body.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter drugs and vitamins.

• History of Pancreatitis: Because sitagliptin has been linked to acute pancreatitis, patients with a history of this condition should be treated with extreme caution. Alternative glucose-lowering therapies may be preferred.
• Moderate to Severe Renal Impairment: While not a contraindication to use, it is a contraindication to the standard 100 mg dose. Failure to adjust the dose in these patients leads to drug accumulation and increased risk of toxicity.
• Heart Failure: Patients with pre-existing heart failure (NYHA Class III-IV) should be monitored very closely, as the DPP-4 class has been associated with potential worsening of heart failure symptoms.

While not extensively documented, there is a theoretical risk of cross-sensitivity between different DPP-4 inhibitors. If a patient has had a serious allergic reaction to another 'gliptin' (such as linagliptin or saxagliptin), healthcare providers should exercise extreme caution or avoid sitagliptin altogether. There is no known cross-sensitivity between sitagliptin and other classes of diabetes drugs like metformin or SGLT2 inhibitors.

> Important: Your healthcare provider will evaluate your complete medical history, including any previous drug allergies and your kidney health, before prescribing Sitagliptin.

Sitagliptin is not approved for use in patients under 18 years of age. While type 2 diabetes is becoming more common in adolescents, the long-term effects of DPP-4 inhibition on growth and development are not fully understood. Clinical trials in this age group have not yet resulted in an FDA-approved indication.

In clinical studies, no overall differences in safety or effectiveness were observed between subjects 65 years and over and younger subjects. However, because sitagliptin is substantially excreted by the kidney, and because elderly patients are more likely to have decreased renal function, care should be taken in dose selection. Renal function should be monitored more frequently in this population to prevent drug accumulation.

Renal impairment is the most significant factor in sitagliptin dosing.

• Mild (CrCl ≥ 50 mL/min): No adjustment (100 mg).
• Moderate (CrCl 30 to < 50 mL/min): 50 mg once daily.
• Severe/ESRD (CrCl < 30 mL/min): 25 mg once daily.

Patients on dialysis can take sitagliptin, and the dose can be given regardless of the timing of the dialysis session.

No dosage adjustment is required for mild to moderate hepatic impairment. For patients with severe hepatic impairment, the pharmacokinetics of sitagliptin have not been established. In such cases, healthcare providers must weigh the benefits against the unknown risks of altered drug metabolism.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are planning to become pregnant or if you are over the age of 65.

| Parameter | Value |

|---|---|

| Bioavailability | ~87% |

| Protein Binding | ~38% |

| Half-life | ~12.4 hours |

| Tmax | 1 to 4 hours |

| Metabolism | Minor (CYP3A4, CYP2C8) |

| Excretion | Renal 87%, Fecal 13% |

• Molecular Formula: C16H15F6N5O (Free base)
• Molecular Weight: 407.31 g/mol (Free base); 523.32 g/mol (Phosphate monohydrate)
• Solubility: Soluble in water and methanol; slightly soluble in ethanol.
• Description: Sitagliptin phosphate is a white to off-white, crystalline, non-hygroscopic powder. It contains a chiral center and is administered as the (R)-enantiomer.

Sitagliptin is the first-in-class Dipeptidyl Peptidase 4 (DPP-4) inhibitor. It is classified as an antihyperglycemic agent. Other drugs in this class include Saxagliptin (Onglyza), Linagliptin (Tradjenta), and Alogliptin (Nesina). Unlike GLP-1 receptor agonists (like Ozempic), which mimic the hormone, sitagliptin preserves the body's own natural hormones.